X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38. It is being evaluated for the treatment of locally-advanced or metastatic triple-negative breast cancer.
Lead Product(s): PLX038
Therapeutic Area: Oncology Product Name: PLX038
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
PLX038 is a long-acting prodrug of the topoisomerase 1 inhibitor, It is being evaluated in phase 1/2 clinical trials for the treatment of primary CNS tumors driven by MYC or MYCN amplifications.
Lead Product(s): PLX038
Therapeutic Area: Oncology Product Name: PLX038
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of DNA synthesis leading to cell death in susceptible tumors.
Lead Product(s): 7-Ethyl-10-Hydroxycamptothecin
Therapeutic Area: Oncology Product Name: PLX038
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
Details:
The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism.
Lead Product(s): Teriparatide
Therapeutic Area: Endocrinology Product Name: PTH(1-34)
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 07, 2020
Details:
PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of DNA synthesis leading to cell death in susceptible tumors.
Lead Product(s): 7-Ethyl-10-Hydroxycamptothecin,Rucaparib Camsylate
Therapeutic Area: Oncology Product Name: PLX038
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
